Inhibitors of BRAF (v-raf murine sarcoma viral oncogene homolog B1) and inhibitors of MEK (mitogen-activated protein kinase kinase) are approved for use in patients with a range of malignancies, including melanoma, colorectal cancer, hepatocellular carcinoma, RCC, and gastrointestinal stroma cell tumors. Here, BRAF is linked to renal cell carcinoma.